Welcome to our dedicated page for INTUITIVE SURGICAL SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
INTUITIVE SURGICAL INC director Craig H. Barratt reported equity compensation activity involving common stock and restricted stock units. On April 30, 2026, a trust associated with him acquired 750 shares of common stock through the exercise of restricted stock units, bringing its indirect holdings to 27,948 shares.
The same day, Barratt received a new grant of 643 restricted stock units, each representing one share of common stock. According to the disclosure, 100% of these RSUs vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service.
Vanguard Capital Management reported beneficial ownership of 26,601,419 shares of Intuitive Surgical common stock, representing 7.49% of the class as of 03/31/2026. The filing shows sole voting power over 3,521,929 shares and sole dispositive power over 26,601,419 shares. The report is signed by Ashley Grim on 04/30/2026.
INTUITIVE SURGICAL INC director Amy L. Ladd reported open-market sales of company Common Stock over two days. She sold 500 shares at $473.46 per share on April 28, 2026, and 119 shares at $463.50 per share on April 29, 2026. After these transactions, she directly holds 120 shares. The filing notes that the activity occurred under a Trading Plan that complies with SEC Rule 10b5-1 and runs through January 29, 2027, indicating the sales were pre-scheduled rather than discretionary.
Myriam Curet McAdams reports a proposed sale of 30,417 shares of Common Stock. The filing lists the sale as a Stock Option Exercise to occur on 04/27/2026 with cash proceeds. The record shows prior dispositions by McAdams in the past three months, including 4,728 shares on 03/03/2026 for $2,303,387.04 and 2,345 shares on 02/27/2026 for $1,171,819.95.
Intuitive Surgical, Inc. reported strong first‑quarter 2026 growth, with revenue rising to $2.77 billion from $2.25 billion a year earlier, driven by higher product and service sales in both U.S. and international markets. Net income attributable to Intuitive increased to $821.5 million, and diluted EPS rose to $2.28 from $1.92, as gross profit expanded to $1.83 billion.
Operating income reached $855.3 million despite higher selling, general and administrative and research and development expenses, reflecting continued investment in growth. Cash flow from operations was strong at $911.9 million, supporting an active capital deployment program including a $533.1 million cash acquisition of European da Vinci and Ion distributors and $1.13 billion of share repurchases at an average price of $489.55 per share.
The company ended the quarter with total assets of $20.11 billion, including $7.98 billion of cash and investments, and stockholders’ equity of $17.60 billion. Management highlighted macroeconomic risks, evolving tariff and trade regimes, and ongoing litigation but noted that credit losses and hedge ineffectiveness remained immaterial in the period.
Intuitive Surgical reported strong first quarter 2026 results, driven by double-digit growth in robotic procedures and system placements. Revenue reached $2.77 billion, up 23% from $2.25 billion a year earlier, as worldwide procedures for da Vinci and Ion systems grew about 17%.
Instruments and accessories revenue rose to $1.69 billion, up 23%, while systems revenue increased to $651 million from $523 million, supported by 431 da Vinci system placements, including 232 da Vinci 5 systems. The installed base expanded to 11,395 da Vinci and 1,041 Ion systems as of March 31, 2026.
GAAP net income attributable to Intuitive Surgical, Inc. was $822 million, or $2.28 per diluted share, compared with $698 million, or $1.92, a year earlier. Non-GAAP net income was $901 million, or $2.50 per diluted share. The company ended the quarter with $7.98 billion in cash and investments and repurchased 2.3 million shares for $1.1 billion. For full-year 2026, Intuitive expects worldwide da Vinci procedure growth of 13.5%–15.5%, non-GAAP gross margin of 67.5%–68.5%, and non-GAAP operating expense growth of 11%–14%.
Intuitive Surgical Inc is listed as the issuer. The Vanguard Group filed an Amendment No. 10 to Schedule 13G/A reporting that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report holdings separately. The filing states amount beneficially owned: 0 and percent of class: 0%. The form is signed by Ashley Grim on March 27, 2026.
Intuitive Surgical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on April 30, 2026, at 3:00 p.m. Pacific. Proposals include electing ten directors, an advisory vote on executive pay, ratifying PricewaterhouseCoopers as auditor, and approving changes to the 2010 Incentive Award Plan.
The proxy details a planned leadership transition in which longtime CEO Gary S. Guthart became Executive Chair and David J. Rosa was promoted to Chief Executive Officer and director. The Board emphasizes strong governance, with eight of ten nominees independent, a separate Chair and CEO, a lead independent director, annual elections, proxy access, and strict anti‑hedging and anti‑pledging rules.
Operationally, for 2025 Intuitive reported revenue of $10,064.7 million, up 21% from 2024, and income from operations of $2,945.5 million, up 25%. Total da Vinci and Ion procedures reached 3,297,100, up 19%, supported by a growing installed base and multiple new FDA and international clearances for its da Vinci and Ion platforms.